Pathways mediating VEGF-independent tumor angiogenesis

Area of Science:

• Oncology
• Ophthalmology
• Molecular Biology

Background:

• Vascular Endothelial Growth Factor (VEGF) inhibitors have advanced cancer and neovascular age-related macular degeneration (AMD) treatments.
• Therapeutic resistance to anti-VEGF drugs is a significant clinical challenge, leading to disease progression.
• The absence of predictive biomarkers hinders patient stratification for anti-VEGF therapies.

Purpose of the Study:

• To review the molecular pathways involved in tumor growth and resistance to anti-VEGF therapies.
• To investigate the contribution of both tumor and non-tumor (stromal) cells to anti-VEGF drug refractoriness.
• To highlight the need for predictive biomarkers in anti-VEGF treatment strategies.

Main Methods:

• Literature review of studies on VEGF pathway inhibitors.
• Analysis of research on tumor cell-intrinsic resistance mechanisms.
• Examination of stromal cell-mediated pathways influencing therapeutic response.

Main Results:

• Both tumor and stromal cell-derived pathways play critical roles in the development of resistance to anti-VEGF therapies.
• Understanding these pathways is essential for overcoming treatment failure.
• Identifying specific biomarkers from these pathways could improve patient outcomes.

Conclusions:

• Resistance to anti-VEGF therapies is multifactorial, involving both malignant and microenvironmental components.
• Further research into tumor and stromal cell pathways is crucial for developing effective resistance-breaking strategies.
• Development of predictive biomarkers is necessary for personalized anti-VEGF treatment approaches.